User:Etienne Robillard/Notebook/Endocannabinoids/Anandamide

From OpenWetWare
Jump to: navigation, search

Intracellular anandamide trafficking as a promoter of neurogenesis acting through presynaptic CB1/FABP binding

The maturation and differentiation of neural stem cells via fatty-acid binding proteins (FABPs) signaling may require anandamide as a promoter of CB1-dependent neurogenesis. [1]

Hippocampal neurogenesis with synaptogenic promoter (DHA) is induced by intracellular and presynaptic CB1 receptor binding to anandamide. [2]

Notes

  • The allosteric activation of PPAR-RXR heterodimer by anandamide (CB1/TRPV1 receptors) may facilitate hippocampal neurogenesis. (Reference needed)
  • Intracellular FABP5 expression may result in anandamide trafficking of heteromeric CB1 receptor. (Reference needed)
  • Adenosine antagonism (caffeine) may potentiate retrograde trafficking of anandamide via heteromization of CB1 receptor. (Reference needed)
  • Anandamide biosynthesis may enhance caffeine-induced diuresis. [3]
  • Anandamide-oxytocin cross-talk (signal transduction) may modulate cellular stress response/vitamin D gene expression?

See also

References

  1. https://www.ncbi.nlm.nih.gov/pubmed/23372698 [Paper1]
    Type-1 (CB1) Cannabinoid Receptor Promotes Neuronal Differentiation and Maturation of Neural Stem Cells
  2. https://www.ncbi.nlm.nih.gov/pubmed/21719698 [Paper2]
    Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide.
  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533417/ [Paper3]
    Diuretic Effects of Cannabinoids
  4. https://www.ncbi.nlm.nih.gov/pubmed/18832445 [Paper4]
    The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway.
  5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC20983/ [Paper5]
    The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.